Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-centre Open Label Randomized Controlled Phase IIB Trial Comparing Vancomycin Versus Daptomycin for the Treatment of MRSA Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations

Next Previous
Trial Profile

A Multi-centre Open Label Randomized Controlled Phase IIB Trial Comparing Vancomycin Versus Daptomycin for the Treatment of MRSA Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daptomycin (Primary) ; Vancomycin
  • Indications Bacteraemia; Bacterial endocarditis; Methicillin-resistant Staphylococcus aureus infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Apr 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 02 Feb 2014 According to ClinicalTrials.gov record study status changed from not yet recruiting to recruiting.
    • 01 Jan 2014 Study design has been published in the Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top